EVEC Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 9

EVEC General Information

Description

Developer of a biotechnology platform designed to obtain antibodies from human peripheral blood lymphocytes to produce fully human antibodies. The company's platform has developed technology for producing fully human antibodies from blood B lymphocytes, which are responsible for antibody production in the human body, enabling medical professionals to cure diseases that have been considered intractable, to develop drugs that are less burdensome for patients, and to develop devices for early diagnosis.

Contact Information

Website
evec.sakura.ne.jp
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2nd floor, Taiko Building
  • 3-1 Minami 2 - jo Nishi 8 - chome, Chuo-ku
  • Sapporo, Hokkaido 060-0062
  • Japan
+81
Primary Industry
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 2nd floor, Taiko Building
  • 3-1 Minami 2 - jo Nishi 8 - chome, Chuo-ku
  • Sapporo, Hokkaido 060-0062
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EVEC Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 31-May-2022 Completed Generating Revenue
4. Accelerator/Incubator 28-Jul-2020 Completed Generating Revenue
3. Later Stage VC 31-Aug-2018 Completed Generating Revenue
2. Later Stage VC 30-Mar-2016 $177K $592K Completed Generating Revenue
1. Seed Round 28-May-2015 $415K $415K Completed Generating Revenue
To view EVEC’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

EVEC Patents

  • 94

    Total Documents Applications and Grants

  • Total Patents Families

  • 29

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

EVEC Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024117057-A1 Antibody or antigen-binding fragment thereof, and immunological measurement device using same Inactive 28-Nov-2022
EP-4471147-A1 Human neutralizing antibody against sars-cov-2 having breadth to variant strains, and antigen-binding fragment thereof Inactive 28-Jan-2022
EP-4471147-A4 Human neutralizing antibody against sars-cov-2 having breadth to variant strains, and antigen-binding fragment thereof Inactive 28-Jan-2022
US-20250101085-A1 Human neutralizing antibody against sars-cov-2 having breadth to variant strains, and antigen-binding fragment thereof Pending 28-Jan-2022
WO-2023145859-A1 Human neutralizing antibody against sars-cov-2 having breadth to variant strains, and antigen-binding fragment thereof Inactive 28-Jan-2022 C07K16/104
To view EVEC’s complete patent history, request access »

EVEC Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EVEC Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Healthcare Innovation Venture Capital Minority
Mitsubishi UFJ Capital Venture Capital Minority
Startup Hokkaido Accelerator/Incubator
Yamaha Motor Corporation Minority
Yamato Shinkin Bank Corporation Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

EVEC FAQs

  • When was EVEC founded?

    EVEC was founded in 2003.

  • Where is EVEC headquartered?

    EVEC is headquartered in Sapporo, Japan.

  • What is the size of EVEC?

    EVEC has 15 total employees.

  • What industry is EVEC in?

    EVEC’s primary industry is Biotechnology.

  • Is EVEC a private or public company?

    EVEC is a Private company.

  • What is EVEC’s current revenue?

    The current revenue for EVEC is .

  • How much funding has EVEC raised over time?

    EVEC has raised $5.3M.

  • Who are EVEC’s investors?

    Healthcare Innovation, Mitsubishi UFJ Capital, Startup Hokkaido, Yamaha Motor, and Yamato Shinkin Bank are 5 of 9 investors who have invested in EVEC.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process